Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.76 |
| ▸ | BLK | P51451 | 2/20 | 0.68 |
| ▸ | FGR | P09769 | 1/20 | 0.68 |
| ▸ | FLT3 | P36888 | 1/20 | 0.68 |
| ▸ | CSK | P41240 | 1/20 | 0.68 |
| ▸ | JAK3 | P52333 | 1/20 | 0.68 |
| ▸ | ITK | Q08881 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20177257 | 1.00 | BTK (0.76) | BTKBLKFGRFLT3CSK | |
| SCHEMBL18235563 | 0.95 | BTK (0.76) | BTKBLKFGRFLT3CSK | |
| SCHEMBL20177356 | 0.95 | BTK (0.76) | BTKBLKFGRFLT3CSK | |
| SCHEMBL24197246 | 0.95 | BTK (0.71) | BTKBLKFGRFLT3CSK | |
| SCHEMBL30332181 | 0.93 | BTK (0.69) | BTKBLKFGRFLT3CSK | |
| SCHEMBL24197251 | 0.93 | BTK (0.69) | BTKBLKFGRFLT3CSK | |
| SCHEMBL24197255 | 0.92 | BTK (0.67) | BTKBLKFGRFLT3CSK | |
| SCHEMBL30331351 | 0.92 | BTK (0.67) | BTKBLKFGRFLT3CSK | |
| SCHEMBL18123564 | 0.91 | BTK (0.74) | BTKBLKFGRFLT3CSK | |
| SCHEMBL6435573 | 0.91 | BTK (0.74) | BTKBLKFGRFLT3CSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10711006-B2 | Selective Bruton's tyrosine kinase inhibitor and use thereof | HANGZHOU HERTZ PHARMACEUTICAL CO., LTD. (CN) | 2020-07-14 | — | — | US | disclosed |
| US-20190276461-A1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2019-09-12 | — | — | US | disclosed |
| WO-2018090792-A1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | 杭州和正医药有限公司 | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276461-A1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | BTK, BMX, KCNK10 | BTK 1/4885BLK 12/4885FGR 805/4885 |
| US-10711006-B2 | Selective Bruton's tyrosine kinase inhibitor and use thereof | BTK, SYK, LYN | BTK 1/4885BLK 35/4885FGR 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.